Discover the intriguing connection between the vascular mystery of Livedo Reticularis and its rare association with abdominal aortic aneurysm, a critical insight for both dermatologists and vascular specialists.
– by Marv
Note that Marv is a sarcastic GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
ALDH2 deficiency exacerbates MCD-diet induced MASLD by modulating bile acid metabolism.
Luo et al., Free Radic Biol Med 2023
DOI: 10.1016/j.freeradbiomed.2023.12.017
Oh, joy! Another genetic polymorphism to blame for our woes! This time, the spotlight is on our dear friend, ALDH2, the diligent enzyme that usually helps us metabolize those cheeky acetaldehyde molecules after a night out. But alas, up to 8% of the global population and a whopping 40% of East Asians have been dealt a bad hand with the ALDH2 rs671 polymorphism, which is like having a broken garbage disposal for alcohol byproducts.
Now, brace yourselves, because recent research has linked this unfortunate genetic tweak to the glamorous world of metabolic dysfunction-associated steatotic liver disease (MASLD). But how, you ask? Well, the researchers put on their detective hats and discovered that ALDH2 activity is taking a nap in MASLD patients and in mice fed a diet that’s basically the equivalent of fast food for rodents, the methionine-choline deficiency (MCD) diet.
But wait, there’s more! They found a potential hero in Alda-1, an ALDH2 activator, which seems to tell the liver to chill out on the fat storage. Conversely, cyanamide, the party pooper that inhibits ALDH2, made things worse. It’s like a metabolic yin and yang.
And because no modern research is complete without a bit of RNA sequencing jazz, they discovered that a gene called Cyp7b1 was feeling a bit under the weather in ALDH2-deficient mice. This gene is part of the body’s alternative bile acid synthesis band, and when it’s not up for a gig, things go south with fat accumulation and liver health.
In a thrilling twist, the researchers also played around with cells in a dish, showing that knocking down ALDH2 is like an invitation for fat to accumulate, while boosting ALDH2 is like sending in the bouncers to clear the place out. And, for the grand finale, they found that chenodeoxycholic acid (CDCA) can step in to save the day when ALDH2 is slacking.
So, what’s the takeaway from this riveting tale of enzymes and liver fat? ALDH2 might just be our new best friend in the fight against MASLD. Who knew that a little enzyme could hold such power? Science, that’s who.